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ABSTRACT
ANALYSIS AND QUANTITATION OF THE CROSS PRESENTATION OF
TUMOR ANTIGENS USING THE HIV PROTEIN TRANSDUCTION
DOMAIN TRANSACTIVATING REGULATORY PROTEIN (TAT) TO
ALTER PRESENTATION
By
Jason Paul Aun
The hallmark of cross presentation is the immune system’s ability to
present an exogenously derived antigen in the class I major histocompatibility
complex (MHC) thus stimulating CD8+ TC cells. Exogenously derived proteins
are normally presented in a MHC class II with the cells stimulating activation of
CD4+ TH cells which do not induce the desired cytotoxic effect. Inducing cross
presentation is important in cancer immunotherapies because the tumor antigens
are presented in the same fashion as exogenous proteins which do not provide the
necessary cytotoxic effect. To stimulate a strong cytotoxic immune response,
facilitating and optimizing cross presentation is paramount.
The purpose of this study was to analyze and quantitate the cross
presentation of tumor antigens coupled with the protein transduction domain HIVTAT. Protein transduction domains have the ability to enter a cell independent of
any known receptor or endocytic activity. Coupling of a modified version of
HER2 with HIV-TAT transferred HER2 to the cytoplasm of the antigen
presenting cells. Labeling indicated that there was a slight increase in MHC class
I expression using TAT-mHER2 compared to mHER2 alone. We conclude that
the results of this study warrant further investigation into optimizing this
promising technology.
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INTRODUCTION
Major Histocompatibility Complexes and Antigen Presentation
The class I major histocompatibility complex (MHC) is present on almost
all nucleated cells and derives antigen from endogenous proteins produced within
the cell. Exceptions to this are immunologically privileged sites such as the
anterior chamber of the eye, neurons in the brain, the cornea, testis, and the uterus
(Goldsby, Kindt, & Osborne, 2000). Cells in these privileged sites express the
tumor necrosis factor Fas ligand on their cell surface, which binds to CD8+ TC
cells expressing Fas receptor (Green &Ware, 1997). This binding causes the
CD8+ TC cells to undergo apoptosis thus avoiding tissue destruction by the
immune system in these privileged sites (Green &Ware, 1997). Additionally,
there is very little expression of MHC class I molecules in these sites, further
inhibiting CD8+ TC cell activity (Green &Ware, 1997). Cornea transplants take
advantage of this immunologic privilege allowing corneas from donors to be
transplanted without rejection by the immune system (Green & Ware, 1997). The
CD8+ TC cell is a specialized T lymphocyte that originates in the bone marrow
and matures in the thymus. These cells are generally cytotoxic in nature and, in
contrast to CD4+ TH cells, kill targeted cells outright rather than strictly activating
a further immune response (Goldsby et al., 2000). Both T cell populations
express distinctive membrane molecules known as cluster of differentiation
molecules (CD8 and CD4) acting as signal transducers to elicit the appropriate
reaction with their respective MHC molecules. T cytotoxic cells express CD8
that interacts with MHC class I molecules and T helper cells express CD4 that
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interacts with MHC class II molecules. The MHC class I derives antigens
endogenously through the cytosolic pathway and the MHC class II derives
antigens exogenously through the endocytic pathway. To elicit a T cell immune
response in either MHC class, extracellular antigens must first be internalized.
After internalization of antigenic proteins through the plasma membrane by
endocytosis from the extracellular fluid into the cytoplasm, internalized antigens
are degraded by the proteasome (Ciechanover, 1994). The proteasome is a large,
cylindrical, multifunctional protease complex with a central channel. This
channel isolates the target protein for degradation, thereby preventing lysis of
other proteins in the cytoplasm (Goldsby et al., 2000). The proteins targeted for
degradation by the proteasome often have the small protein ubiquitin attached to
them (Ciechanover, 1998). Ubiquitin’s primary function is to mark proteins for
proteolysis through a complex cascade of enzymes (Ciechanover, 1998). Proteins
marked for degradation are typically short-lived (internalized antigens),
misfolded, or have a dissociation of subunits (Hershko & Ciechanover, 1998).
Once conjugated to ubiquitin, the proteasome can degrade the marked protein by
cleaving peptide bonds between two or three different amino acid combinations in
an ATP-dependent process generating a variety of peptides terminating with
hydrophobic or basic residues (Ciechanover, 1998). Two subunits of the
proteasome, LMP2 and LMP7 are encoded within the MHC gene cluster and are
induced by increased levels of the cytokine, interferon-γ (IFN-γ); another subunit,
LMP10, is also induced by IFN-γ but it is not MHC encoded (Niedermann et al.,
1995). The peptidase activities of proteasomes containing LMP2, LMP7, and
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LMP10 preferentially generate peptides with basic and/or hydrophobic residues
that bind to MHC class I molecules (Niedermann et al., 1995). These
hydrophobic, and occasionally basic, residues that are part of the generated
peptides act as anchor residues (at the carboxyl [C] terminal) to bind with the
MHC class I molecule. All peptides examined to date that bind to MHC class I
molecules contain a carboxyl-terminal anchor (Goldsby et al., 2000). These
peptides also possess an anchor residue at position two or positions two and three
at the N terminal residue and at the C terminal residue pointing into the cleft
which are also important for binding (Lankat-Buttgereit & Tampé, 2002). These
antigenic peptides destined for interaction with the MHC class I molecule number
only eight to 10 residues because the conformation of the peptide-binding cleft in
MHC class I molecules is a closed groove (Goldsby et al., 2000). Conversely,
MHC class II molecules have an open peptide-binding cleft accommodating
slightly longer peptides of 13-18 amino acids and do not require
basic/hydrophobic residues for peptide binding (Goldsby et al., 2000). These
open and closed peptide-binding clefts arise from variations in the polymorphic
residues, which are the amino acids that vary among different MHC alleles
(Abbas & Lichtman, 2001). These residues are located in and around the cleft
which is composed of paired α-helices resting upon a floor made up of an eightstranded β-pleated sheet (Abbas & Lichtman, 2001).
The next challenge the cell must overcome is transporting the newly
cleaved peptides to the rough endoplasmic reticulum (RER) where the MHC
molecules are being synthesized by polyribosomes (Abbas & Lichtman, 2001).
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This is accomplished by the transporter associated with antigen processing (TAP),
a member of the ATP-binding cassette transporter family, which is a membrane
spanning heterodimer consisting of TAP1 and TAP2 (Abbas & Lichtman, 2001;
Solheim, Carreno, & Hansen, 1997). The TAP-transporter translocates peptides
generated by the proteasome complex from the cytosol and actively pumps them
into the lumen of the RER (Abbas & Lichtman, 2001; Lankat-Buttgereit &
Tempé, 2002). Major histocompatibility complex class I loading includes not
only TAP but the components tapasin, calreticulin, Erp57, MHC class I heavy
chain and MHC class I-β2 microglobulin (β2m) dimers (MHC class I light chain)
(Ackerman, Kyritsis, Tampé, & Cresswell, 2003; Guermonprez, et al., 2003;
Houde, et al., 2003). The tapasin, calreticulin, and Erp57 function as chaperone
proteins. Tapasin brings TAP into proximity with the MHC class I molecule and
allows it to acquire an antigenic peptide (Ortmann et al., 1997). Calreticulin is
responsible for the folding and peptide-loading of newly synthesized molecules of
the MHC class I protein (Culina, Lauvau, Gubler, & van Endert, 2004). The
function of the resident ER thiol reductase Erp57 in MHC class I peptide
assembly and loading is thought to contribute to the formation of disulfide bonds
during the maturation of MHC class I chains (Lankat-Buttgereit & Tempé, 2002).
Within the RER membrane, the newly synthesized MHC class I α chain associates
with calnexin (a chaperone protein that assists in protein folding) until β2m binds
to the α chain (Goldsby et al., 2000). The MHC class I α chain-β2m heterodimer
then binds to calreticulin and the TAP-associated protein tapasin (Solheim et al.,
1997). The physical association of the α chain-β2-m heterodimer with the TAP
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protein promotes peptide capture by the class I molecule before the peptides are
exposed to the luminal environment of the RER, where it has been demonstrated
that unbound peptides are rapidly degraded (Goldsby et al., 2000). As a result of
binding, the MHC class I molecule becomes stable and can dissociate from the
calreticulin and tapasin (Solheim et al., 1997). The MHC class I α chain-β2-m
heterodimer with its associated peptide fragment is transported from the RER to
the plasma membrane by the Golgi apparatus, where it is expressed on the surface
of the antigen-presenting cell (APC) and displayed to CD8+ TC cells (Goldsby et
al., 2000).
The class II MHC is primarily presented on macrophages, dendritic cells
(DCs), B lymphocytes, and endothelial cells which present antigens that have
been internalized in phagocytic/endocytic vesicles (Abbas & Lichtman, 2001).
Dendritic cells, which are professional antigen-presenting cells APCs, are the
most important cells for initiating primary T cell responses and primarily present
MHC class II (Abbas & Lichtman, 2001). After internalization into the
endosome, the antigen is degraded into peptide fragments by proteolytic enzyme
digestion by moving through three increasingly acidic compartments: early
endosomes (pH 6.0–6.5); late endosomes or endolysosomes (pH 5.0–6.0); and
lysosomes (4.5–5.0) (Goldsby et al., 2000). The mechanism by which
internalized antigen moves from one endocytic compartment to the next has not
been conclusively demonstrated (Goldsby et al., 2000). The fragments are
attached to MHC class II molecules which prior to coupling with the antigen
peptide was bound to a class II invariant peptide (CLIP) in the RER; this invariant
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chain stabilizes the class II molecule before it has acquired the antigenic peptide
(Goldsby et al., 2000). To load the peptide onto the newly synthesized MHC
class II molecule, the peptide exchange molecule HLA-DM facilitates the
removal of CLIP from the binding cleft allowing peptides derived from the
endocytosed protein to join in the endosomal compartment (possibly via the Golgi
apparatus) (Abbas & Lichtman, 2001). The endosome is an intracellular
membrane-bound vesicle into which extracellular proteins are internalized during
antigen processing (Abbas & Lichtman, 2001). A subset of MHC class II-rich
endosomes (MIIC) specialize in antigen processing and presentation by the class
II MHC pathway (Abbas & Lichtman, 2001). The antigen/MHC class II molecule
complex is then transported via the Golgi apparatus to the cell surface for
expression on the APC and displayed to CD4+ TH cells (Abbas & Lichtman,
2001).
Cross Presentation of Antigens
There is increasing evidence of a phenomenon known as cross
presentation; that is exogenous proteins internalized by phagocytosis or
pinocytosis, are presented in MHC class I molecules to CD8+ T cells (Saveanu &
van Endert, 2005). Cross presentation is a mechanism by which professional
APCs (typically DCs) display exogenous and self-antigens of another cell (such
as a tumor cell) and activate (or prime) a naïve CD8+ TC cell (Abbas & Lichtman,
2001). This occurs, for example, when a cancerous cell is ingested by a
professional APC, and the tumor antigens are processed and presented in
association with the MHC class I molecules, as opposed to MHC class II (Abbas
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& Lichtman, 2001). The professional APC also provides costimulation to fully
activate the T cell which involves the interaction of two proteins, CD80 on the
APC and CD28 on the T cell (Abbas & Lichtman, 2001). In vivo, DCs acquire
endogenous antigens from infected cells in the periphery, and then migrate to the
lymph nodes where they display antigenic peptides in association with MHC class
I molecules (Groothuis & Neefjes, 2005). The mechanism by which cross
presentation occurs is poorly understood but recent research shows that it occurs
in early phagosomes prior to the formation of the phagolysosome (Saveanu & van
Endert, 2005). The phagosome is an intracellular vacuole formed by the fusion of
pseudopodia around a particle undergoing phagocytosis (Goldsby et al., 2000).
The phagosome fuses with a lysosome to form a phagolysosome (Abbas &
Lichtman, 2001). Early macrophage phagosomes are formed mainly by ER
membranes; these harbor Sec61 which has been shown to retrotransport ER
proteins to the cytoplasm for degradation by the proteasome (Saveanu & van
Endert, 2005; Gagnon, 2002). The early phagosomes contain all the functional
elements for TAP-dependent loading of MHC class I molecules (Saveanu & van
Endert, 2005). By completely separating the processing of exogenous antigens
from that of endogenous ones, the existence of an autonomous ER-phagosome
contributes to the efficiency of cross presentation of ER-mediated phagocytosed
material (Saveanu & van Endert, 2005). The uptake of particulate phagocytosed
antigens that eventually become cross presented is much more efficient than the
uptake of soluble antigens through pinocytosis (Kovacsovics-Bankowski,
Benacerraf, & Rock, 1993; Saveanu & van Endert, 2005). This was demonstrated
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by Ackerman et al. (2003), by incubating DCs with a soluble peptide fragment of
US6 from the human cytomegalovirus (HCMV). US6 is a HCMV-encoded type I
glycoprotein peptide that inhibits peptide trafficking from the cytosol into the
endoplasmic reticulum and subsequent peptide loading of MHC class I molecules
(Kyritsis et al., 2001). US6 inhibits peptide loading by inhibiting TAP function
by binding to its luminal domain (Kyritsis et al., 2001). The result of this
inhibition was a reduction (up to 90%) of MHC class I molecules being displayed
on the cell surface and inhibition of about 70% of the cellular TAP transporter
pool leading to inhibition of endogenous antigen presentation (Kyritsis et al.,
2001). This shows that US6 had to gain access to the complete perinuclear ER
(Kyritsis et al., 2001). To corroborate this, Kyritsis et al. (2001) incubated β2mdeficient DCs with exogenous β2m and found that the exogenous β2m localizes
rapidly to the perinuclear ER, associates with MHC class I heavy chains bearing
ER-typical immature glycans, reconstitutes cell surface class I expression, and
normalizes presentation of endogenous antigen (Kyritsis et al., 2001; Saveanu et
al., 2005). Both US6 and β2m do not access the ER of macrophages, due to the
rapid degradation of endocytosed soluble proteins in macrophages (Saveanu et al.,
2005). Limiting proteolytic activity in early endocytic vesicles is another
requirement for efficient cross presentation—as demonstrated by macrophages,
whose aggressive endocytic machinery focuses on pathogen destruction at the
expense of cross presentation capacity (Saveanu et al., 2005).
Traditionally, the CD8+ paradigm states that CD8+ T cells can only
recognize endogenously synthesized antigens, whereas CD4+ T cells recognize
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exogenous antigens (Larsson, Fonteneau, & Bhardwaj, 2001). This paradigm
failed to take into account the observation that immunity develops spontaneously
to viruses that cannot infect professional APCs (such as Epstein-Barr virus), or to
tumors and allografts that by themselves are poor APCs (Larsson et al., 2001). In
1976, Bevan showed that mice immunized with cells that express foreign minor
histocompatibility (HC) antigens mounted an antigen-specific response that was
restricted to self-class I MHC, demonstrating that exogenous pathways are
important in the induction of CD8+ T cell responses (Larsson et al., 2001). Minor
HC antigens are proteins expressed outside of the MHC loci; these antigens are a
contributing factor to graft rejection and are only recognized when they are
presented in the context of self-MHC molecules unlike major histocompatibility
antigens which are recognized directly by TH and TC cells, i.e. alloreactivity
(Goldsby et al., 2000). This study formed the basis of the postulate that antigens
presented exogenously by donor cells to professional APCs were able to be
presented on MHC class I molecules, i.e. cross presentation (Larsson et al., 2001).
Several features were found from these cross presentation studies: efficient cross
presentation of antigen required bone-marrow-derived cells such as dendritic
cells, diverse groups of antigens could access MHC class I by exogenous
pathways, and in some cases, cross presentation was dependent upon the presence
of TAP, suggesting that antigens have to access the cytoplasm of professional
APCs to converge with conventional endogenous processing pathways (Larsson
et al., 2001).
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It has been demonstrated that the components of the Sec61 complex, a
translocon that forms a pore on the ER membrane, are also associated with
phagosomes (Houde et al., 2003). Sec61’s primary function is the cotranslational transfer of newly synthesized proteins into the RER (Lehner &
Cresswell, 2004). It has been hypothesized that proteins internalized through
endocytosis are transferred from components of the Sec61 complex (Houde et al.,
2003). After transferring from the endosome to the cytosol, the proteins would
undergo ubiquitination and proteasomal degradation in the cytoplasm to generate
the correct peptides for MHC class I loading (Houde et al., 2003). These peptides
would be transported into either the RER lumen through the TAP complex to
form MHC class I-peptide complexes (Houde et al., 2003) or be transported back
into the same phagosome from which they originated (Ackerman, Kyritsis,
Tampé, & Cresswell, 2005; Guermonprez et al., 2003). The MHC class I-peptide
complexes formed in the RER would be transported to the cell surface through the
secretory pathway, while the MHC class I-peptide complexes formed in the
phagosomes would be transported to the cell surface through the membrane
recycling machinery of endocytic/phagocytic organelles (Houde et al., 2003).
After the antigen has been loaded onto the MHC class I molecule, it is then
transported to the cell surface by the Golgi apparatus and then with an exocytic
vesicle where it is finally expressed on the surface of the APC and displayed to
CD8+ TC cells.
Albert et al. (1998) demonstrated that human DCs could phagocytose
apoptotic influenza-infected monocytes and stimulate resting CD8+ T cells to
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develop into cytotoxic T lymphocytes (CTLs). Dendritic cells pulsed with
apoptotic tumor cells also primed tumor specific CTLs (Larsson et al., 2001).
Additionally, studies showed that splenic DCs isolated after in vivo priming with
ovalbumin (OVA)-loaded β2m-deficient splenocytes presented OVA antigens to
OVA-restricted MHC class I CD8+ T cells (Larsson et al., 2001). Cross
presentation was TAP-dependent and restricted to the lymphoid CD8+ DC subset,
even though myeloid CD8- DCs acquire antigens in vivo (den Haan, Lehar, &
Bevan, 2000); CD8- DCs lack the co-receptor T cell accessory molecule CD8
which is necessary for adhesion and signal transduction and thus are unable to
cross present (Abbas & Lichtman, 2001; den Haan et al., 2000).
Studies have also been done on patients with paraneoplastic cerebellar
degeneration (PCD) who also had limited underlying cancer (usually breast or
ovarian) (Albert et al., 1998). These patients also had antibodies toward
complementarity determining region 2 (CDR2) antigen, which is normally
expressed in immune-privileged sites (Albert et al., 1998). Dendritic cells from
these patients phagocytosed apoptotic tumor lines that expressed CDR2 and
induced potent anti-CDR2 cytolysis from autologous T cells (Albert et al., 1998).
These data suggest that, in PCD, cross presentation of tumor antigens by DCs
provides the initial stimulus for CTLs in vivo (Larsson et al., 2001). Several
additional studies have confirmed that human DCs can cross present antigens
from apoptotic tumor cells to CD8+ T cells (Larsson et al., 2001). As evident by
these studies, cross presentation might be essential for the generation of tumor
immunity.
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Protein Transduction Domains
It has proven difficult to generate protective CD8+ T cell immunity to
microbes, viruses, and cancer in humans with the current vaccine strategies
employing peptides, plasmid DNA, subunit vaccines, and inactivated viruses
(Larsson et al., 2001). One possible reason is that delivery of exogenous antigens
to DCs has not been optimized (Larsson et al., 2001). Protein transduction
domains (PTDs) have been described as short peptides that are able to penetrate
the plasma membrane and this transducing property can be conferred upon other
proteins when fused with the PTD (Ford, Souberbielle, Darling, & Farzaneh,
2001). Several PTDs have been described in recent years, the human
immunodeficiency virus-1 transactivator of transcription protein (HIV-1 TAT) in
1998, Drosophila Antennapedia homeotic transcription factor (Antp) in 1991, and
herpes-simplex-virus-1 DNA-binding protein viral protein 22 (HSV VP22) in
1997. Neither the mechanism of protein transduction nor the biological function,
if any, of PTDs is understood. It has been demonstrated that transduction of
PTDs does not occur through the normal receptor-, transporter-, endosome-, or
absorptive-endocytosis-mediated processes (Schwarze, Hruska, & Dowdy, 2000).
Treatment with drugs that inhibit cellular transport does not effect transduction
(Del Gaizo Moore & Payne, 2004). It has been demonstrated that linkage of
molecules thought to be unable to penetrate the plasma membrane to PTDs
confers the ability of the nonpermanent molecule to cross the membrane. In
1994, Fawell and colleagues demonstrated that large molecules such as βgalactosidase (β-gal), horseradish peroxidase, Rnase A and domain III of
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Pseudomonas exotoxin A, when chemically cross-linked with TAT peptides were
carried into cells in vitro. Fawell et al. (1994) also demonstrated that β-gal
activity was present in vivo in liver, kidney, and lung tissues as well as heart
muscle fibers, the red pulp area of the spleen and even in the central nervous
system indicating the TAT-β-gal fusion was able to cross the blood-brain barrier.
One possible mechanism of entry proposed by Schwarze et al. (2000) involves
direct penetration of the lipid bilayer caused by the localized positive charge of
the PTD in which the momentum of the molecule drives the covalently attached
‘cargo’ into the cytoplasm (Figure 1). After transduction, the membrane
energetics would then favor reformation of an intact lipid bilayer (Schwarze et al.,
2000). The composition of PTDs have a moderate to high number of the basic
amino acids arginine and lysine, which might be important for contact with the
negatively charged inner face of the lipid bilayer (Schwarze et al., 2000).
Schwarze’s group has suggested that denatured proteins may be transduced more
efficiently than correctly folded proteins and then correctly refolded by
chaperonins such as heat shock protein 90 (HSP90) also shown in Figure 1 (Ford
et al., 2001; Schwarze et al., 2000).
HER2
The human epidermal growth factor receptor (EGFR) family of tyrosine
kinases consists of EGFR (HER1, erbB1), HER2 (erbB2, HER2/neu), HER3
(erbB3) and HER4 (erbB4) (Slamon et al., 1989). The human epidermal growth
factor receptor HER2 was discovered in the early 1980s, when a mutationally
activated form of its murine homolog neu was identified in a search for oncogenes
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in a carcinogen-induced rat tumorigenesis model (Moasser, 2007; Shih, Pady,
Murray, & Weinberg, 1981; Slamon et al., 1989). Its human homologue, HER2
was simultaneously cloned and found to be amplified in a breast cancer cell line
(King, Kraus, & Aaronson 1985; Moasser, 2007). The transforming potential of
HER2 differs from that of neu in that HER2 is tumorigenic through
overexpression while neu requires mutational activation (Moasser, 2007). The
relevance of HER2 to human cancer was established when it was discovered that
approximately 25–30% of breast cancers have amplification and overexpression
of HER2 and these cancers have worse biologic behavior and prognosis (Moasser,
2007, Slamon et al., 1989). The expressed protein, HER2, is a transmembrane
protein that spans the cell membrane seven times and is approximately 500 amino
acids in length. Human epidermal growth factor receptor 2’s normal function is
as a cell membrane surface-bound receptor tyrosine kinase involved with signal
transduction leading to cell differentiation and growth (Olayioye, 2001). Varied
mechanisms for HER2 involvement in growth and differentiation have been
proposed; however, no unified model has gained wide acceptance (Moasser,
2007). Three mechanistic models that have been proposed involve abnormalities
in signaling and all involve the overexpression of HER2, either in homodimeric
form or heterodimeric form coupled with either EGFR or HER3. All three
models point to a cascade effect of signals leading to any of the following: G1/S
cell cycle deregulation, loss of cellular polarity, dysregulation of cyclin D1 (a
G1/S regulator), tumor invasion, tumor proliferation, and an increase in tumor
metabolism and survival (Moasser, 2007). There are typically 25 to 50 copies of
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the HER2 gene in normal cells (Moasser, 2007). In cancerous cells there can be a
40- to 100-fold increase in HER2 expression, resulting in up to two million
receptors expressed on the tumor cell surface (Lohrisch & Piccart, 2001; Moasser,
2007; Venter, Tuzi, Kumar, & Gullick, 1987) illustrating the sheer number of
aberrant signaling receptors.
Human epidermal growth factor receptor 2 is an attractive target for drug
therapy because it is a cell membrane receptor-based protein allowing for
antibody-based treatments to be utilized. Several HER2-targeting therapeutic
strategies have been utilized, most notably the humanized monoclonal antibody
(mAb) trastuzumab. Trastuzumab’s exact role in inhibiting HER2 tumors has not
been fully elucidated (Moasser, 2007). It is thought that trastuzumab acts on the
extracellular segment of HER2 causing cellular arrest during the G1 phase of the
cell cycle thereby reducing growth of the tumor (Kute et al., 2004). Treating
patients with early-stage HER2 positive tumors with trastuzumab in conjunction
with chemotherapy (after tumor resection) has shown significant prolonging of
disease-free survival and reduction of disease recurrence (Moasser, 2007).
However, 70% of patients do not respond to trastuzumab and resistance to the
drug develops rapidly in almost every patient treated (Kute et al., 2004). Another
negative aspect of trastuzumab treatment is cost; the full course of treatment is
approximately $70,000 (Fleck, 2006).
Tyrosine kinase inhibitors (TKIs), such as imatinib, have shown promise
as well for inhibiting HER2 positive tumor growth. Potentially, TKIs have a
desired advantage over monoclonal antibodies such as trastuzumab (Moasser,
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2007). While trastuzumab is only able to bind to the extracellular segment of
HER2 (being an antibody, which are cell-impermeable), TKIs are cell-permeable
and can potentially inhibit the ligand-dependent and -independent kinase activity
of HER2 residing within the intracellular domain (Moasser, 2007). This strategy
could be effective because kinase activity is essential for the oncogenic function
of HER2 (Moasser, 2007). Imatinib has shown positive treatment results in
chronic myeloid leukemia and gastrointestinal stromal tumors and these successes
led to treatment of HER2-positive tumors as well (Arteaga, 2003). However,
TKIs are not target-specific like antibodies and their off-target effects potentially
limit their therapeutic value compared with antibodies (Moasser, 2007). The
development of HER2-specific TKIs has shown mixed to mediocre results as well
(Moasser, 2007).
Trastuzumab and TKIs are two examples of treatments that have, at best,
moderate potential. Using PTDs is an attractive methodology because of their
ability to penetrate virtually any cell, independent of a cell receptor. This gives
rise to the potential of using PTDs to elicit an immune response by coupling an
antigen to the PTD that can be processed by dendritic cells and then presented to
T cells. This would potentially bypass any problems related to resistance,
specificity, or toxicity.
Current Approach
The current study takes advantage of PTD technology that may allow the
transport of a protein directly into the cytosol and cause the protein to be
processed by the endogenous antigen pathway and be expressed preferentially in a
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MHC class I molecule. For this study, TAT PTD was used. The transactivator of
transcription protein has shown moderate promise in stimulation of T cells in vitro
in previous studies conducted in our laboratory. TAT will be coupled with a
modified version of a human epidermal growth factor receptor protein, HER2.
The modified construct was produced (linked with PTD-TAT) by cloning into a
bacterial vector and consists of four components: TAT, the extracellular
component of HER2, the eight amino acid sequence SIINFEKL from ovalbumin
(OVA257-264), and the intracellular component of HER2. Collectively, this
construct is denoted as TAT-mHER2 (m denotes modified).
One of the approaches that has been widely used in cancer immunotherapy
has been to use antigens found on tumor cells to stimulate a cytotoxic immune
response. By isolating APCs and then exposing them to the specific antigen,
either in its native or a modified form, the APCs on reinfusion into the patient
may be able to stimulate a specific immune response directed at the tumor cells
bearing those antigens. However, one of the keys to immunotherapy is the ability
to present antigens in MHC class I molecules and stimulate CD8+ T cytotoxic
cells since the majority of proteins presented in MHC class I molecules are
cytoplasmic and newly synthesized proteins which are degraded by the
proteasome. These peptides produced by the proteasome are transported into the
ER by TAP. Peptides derived from exogenous antigens such as would be the case
if APCs were pulsed with soluble antigen and internalized by endocytosis are
thought to be displayed primarily by MHC class II molecules and subsequently
stimulate CD4+ T helper cells. Our hypothesis is that using protein transduction
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domains, short peptides that are able to penetrate the plasma membrane, may
confer their transducing property on other proteins when expressed as fusions
with the PTD. The advantage of this technology, over just pulsing APCs with
soluble antigen, would be that transport of a protein antigen directly into the
cytosol might allow the antigen to be processed by the endogenous antigen
pathway and expressed preferentially in a MHC class I molecule.
Using mHER2 alone (soluble protein) and TAT-mHER2 (soluble protein
fused to a PTD) we hypothesize that there will be a greater degree of MHC class I
presentation as measured by immunofluorescence using a monoclonal antibody
specific for presentation of our mHER2 in MHC class I molecules.
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MATERIALS AND METHODS
TAT-mHER2 and mHER2 Production
A DNA sequence was designed for the TAT protein and the mHER2
component which were then linked. This sequence was ligated into a plasmid
vector (pTriEX, Novagen) and then transformed to Escherichia coli cells (Figure
2). The vector (pTriEX) was first transformed into Novablue E. coli cells
(Novagen) which produce high yields of plasmids. The plasmids were isolated
using a plasmid isolation kit from Qiagen and then the plasmids were used to
transfect a second E. coli strain, Rosetta (DE3) pLacI cells. These cells are
engineered to express large quantities of repressor proteins from the LacI
regulatory gene to allow for optimal cell growth. After induction with isopropyl
β-D-1-thiogalactopyranoside (IPTG), which binds to the repressor proteins
leading to inactivation, large amounts of the target protein are produced by the lac
operon. The first gene inserted into the plasmid was TAT (with a linker) followed
by extracellular HER2 (HER2EC1/2), SIINFEKL (amino acid residues 257-264
of chicken ovalbumin), and intracellular HER2 (HER2IC1/4) (the mHER2
plasmid construct did not have the TAT sequence). Selection for transformed
TAT-mHER2/mHER2 expressing cells was achieved by taking advantage of
selective antibiotic resistance to carbenicillin and chloramphenicol. These
antibiotics were added to the initial culturing medium (carbenicillin 50 µg/ml,
chloramphenicol 34 µg/ml), Luria-Bertani (LB) agar, to select for cells containing
the recombinant DNA. After culturing, a single colony was transferred to LB
broth, also treated with carbenicillin and chloramphenicol (same concentrations),
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to allow the cells to proliferate overnight. Expression of TAT-mHER2/mHER2
protein was achieved by activating transcription of the lac operon with 1 mM
IPTG which was added when optimal levels of E. coli growth were reached. A
spectrophotometer set to 600 nm absorbance was used to find the optical density
(OD) of the broth. When the OD600 reached an absorbance of 0.5 (equal to 5x105
colony forming units/ml), with sterile LB broth used as the standard, the IPTG
was added and incubated overnight. The transcription of TAT-mHER2/mHER2
resulted in the formation of cytoplasmic inclusion bodies.
Isolation of TAT-mHER2 and mHER2 Inclusion Bodies
The inclusion bodies were isolated and then solubilized in denaturing
conditions in 6 M guanidine hydrochloride (GuHCl). After sufficient levels of E.
coli growth were reached in the LB broth centrifugation was used to pellet the E.
coli cells and the broth was removed by aspiration. The resulting E. coli pellet
was resuspended in a buffered solution of 50 mM Tris and 25% sucrose at a pH of
8.0 (buffer A). Buffer A was prepared from a stock buffer consisting of 20 mM
Tris and 100 mM NaCl at a pH of 8.0; buffers B and C, discussed below, are
made from this stock buffer as well. After resuspension in buffer A, the E. coli
cells were then lysed with a buffered 8.0 pH lysing solution consisting of 1%
deoxycholate, 1% Triton X-100 (a nonionic surfactant), 0.3 mg/ml Sigma
lysozyme, and 1 mM Calbiochem Protease Inhibitor Cocktail Set III (buffer B).
After mixing the E. coli cells in the suspension of buffers A and B for 15 minutes,
a solution of 1 mM MgCl2 and 0.02 µl/ml of benzonase endonuclease was added
to the suspension to remove all DNA and RNA components and reduce viscosity.
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The lysates were then centrifuged at 6,800 x g for 10 minutes at 4° C in a Sorvall
RC-5B centrifuge using the SLA-3000 rotor to pellet the lysates; the supernatant
(buffer A and buffer B) was removed by aspiration and discarded. The lysate
pellet was resuspended in a buffered solution consisting of 0.5% Triton X-100
(buffer C), centrifuged again at 6,800 x g for 10 minutes at 4° C, and the
supernatant was aspirated; this was repeated two more times. The pellet was then
resuspended in stock buffer followed by centrifugation at 6,800 x g for 10 minutes
at 4° C and then the supernatant aspirated again. The pellet was resuspended
again in stock buffer, transferred to an Oak Ridge tube and centrifuged at 11,000
x g for 10 minutes at 4° C. The supernatant was aspirated and discarded leaving a
pellet consisting of purified inclusion bodies. The purified pellet of inclusion
bodies was resuspended in an 8.0 pH solubilization buffer consisting of 20 mM
Tris, 6 M GuHCl, 0.5 M NaCl, 10 mM imidazole, and 5 mM β-mercaptoethanol.
The inclusion bodies were placed on a rotary mixer for 55 minutes at room
temperature to ensure pellet resuspension. The Oak Ridge tube containing the
suspension was then centrifuged at 9,800 x g for 10 minutes at 4° C to pellet the
non-protein components of the suspension. The remaining supernatant, consisting
of the solubilized inclusion bodies (protein), was sterile vacuum filtered through a
0.22 µm cellulose acetate filter to remove any additional particulates that did not
pellet and potential bacterial contaminants.
Sample Quantification
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
confirmed the presence of TAT-mHER2/mHER2 protein (Figure 3) using
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Invitrogen Pre-Cast NuPAGE Novex 4-12% Bis-Tris Gels. One hundred
microliters of the TAT-mHER2/mHER2 protein samples (from the inclusion body
isolation above), both in volumes of approximately 15 ml after sterile vacuum
filtration, were prepared for SDS-PAGE first by suspending in 100% ethanol to
take the protein out of solution from the 6 M GuHCl. The sample was cooled at 20° C for 10 minutes prior to micro-centrifugation for eight minutes at 4° C to
pellet the protein. After removal of the supernatant, 90% ethanol was added,
vortexed briefly to resuspend the pellet, and then cooled again at -20° C for 5
minutes prior to micro-centrifugation at 16,000 x g for eight minutes at 4° C. The
supernatant was removed, the pellet allowed to air-dry and then resuspended in
distilled water (dH2O), 500 mM Invitrogen dithiothreitol, and 4 X lithium dodecyl
sulfate PAGE (LDS-PAGE) buffer (Invitrogen). Two molecular weight standards
were used to verify that the electrophoresis had run properly and to find the
appropriate weight as well as presence of the TAT-mHER2/mHER2 proteins.
Invitrogen SeeBlue® Plus2 Pre-Stained Standard allowed visualization of weight
ranges during electrophoresis and Invitrogen Mark12™ Unstained Standard
allowed close estimation of the TAT-mHER2/mHER2 molecular weight. The
pre-cast gels were loaded with TAT-mHER2/mHER2 samples and both molecular
weight markers and run completely submerged in an Invitrogen Novex Mini-Cell
gel box with NuPAGE MOPS SDS Running Buffer (Invitrogen) and NuPAGE
Antioxidant (Invitrogen) for 54 minutes at 200 volts. After completion of
electrophoresis, the pre-cast gel was removed from the gel box, opened, rinsed
with dH2O, and placed into a staining tray to stain overnight in Invitrogen
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SimplyBlue™ SafeStain on an agitator. After staining, the gel was de-stained
overnight with dH2O then prepared for permanent archiving and easy observation
of results by placing the gel between two sheets of cellophane soaked in
Invitrogen Gel-Dry Solution and allowed to dry over night using an Invitrogen
DryEase Gel Drying System.
TAT-mHER2 and mHER2 Protein Purification
TAT-mHER2 and mHER2 protein purification was achieved by protein
capture on a nickel ion (Ni++) chelating column, through Pharmacia Fast Protein
Liquid Chromatography (FPLC). The plasmid transfected to the E. coli genome
carried a sequence to code for six histidine amino acids to act as a tag for
chelating with nickel sulfate (NiSO4). An GE Healthcare HiTrap™ 5 ml
Chelating HP Column was loaded with 100 mM of NiSO4 and then washed with
solubilization buffer to remove any excess NiSO4. Imidazole in the solubilization
buffer (20 mM Tris, 6 M GuHCl, 0.5 M NaCl, 10 mM imidazole, 5 mM βmercaptoethanol, pH 8.0) was used to elute non-specific proteins (less than six
histidine tags) off the column into 20 mM imidazole fractions. The 20 mM
imidazole was the result of the solubilization buffer (10 mM imidazole) mixed
with an elution buffer consisting of 20 mM Tris, 6 M GuHCl, 0.5 M NaCl, and
300 mM imidazole at pH of 8.0. Specific proteins (six histidine tags) were eluted
off the column using elution buffer alone. Next, the protein solubilized in the
solubilization buffer was loaded onto the column. The histidine tags present on
the protein allowed chelation with the NiSO4, forming a protein-Ni++ complex
bound to the column. These Ni++-bound proteins were eluted off the FPLC
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column with imidazole. The non-specific proteins were eluted off the column
first in 20 mM imidazole fractions collected in 10 ml increments. Determining
when to collect the appropriate 20 mM imidazole fraction was achieved when the
UV spectrophotometer on the FPLC showed a constant, mid-range plateau as the
elution buffer moved through the column. When the UV spectrometer showed a
significant increase in absorbance, 1 ml fractions were collected which consisted
of 300 mM imidazole and these fractions consisted of the specifically-bound
target protein (six histidine tags). Fraction collection was stopped when the UV
peaks began to decline. All the 1 ml fractions were combined and 0.5 M
ethylenediaminetetraacetic acid (EDTA) was added.
The purified TAT-mHER2/mHER2 protein was resuspended in 20 mM
Tris, 6 M GuHCl, 0.5 M NaCl, 2 mM EDTA and was injected into a Pierce SlideA-Lyzer dialysis cassette then dialyzed against a refolding/renaturation buffer
consisting of 100 mM Tris, 0.5 M arginine, 2 mM EDTA, 2.5 mM reduced
glutathione, and 0.5 mM oxidized glutathione at a pH of 8.0 to remove the GuHCl
and to refold and renature the protein. This was done for 12 hours at 4° C on a
stir plate. After 12 hours, the buffer was replaced with fresh
refolding/renaturation buffer and dialyzed for another 12 hours at 4° C on a stir
plate. The refolding/renaturation buffer was then replaced with phosphate
buffered saline (PBS) and dialyzed again for 12 hours and repeated once more
with fresh PBS for another 12 hours, both at 4° C on a stir plate. The refolded
and renatured protein, now suspended in PBS, was suitable for in vitro use.
Lastly, the protein was concentrated through ultrafiltration using an Amicon
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Ultra-15 Centrifugal Filter Device (10,000 kDa nominal molecular weight limit).
The concentration of TAT-mHER2/mHER2 protein was determined by
bicinchoninic acid assay (BCA). A Molecular Devices SpectraMax Plus
Spectrophotometer (absorbance at 570 nm) operated by SOFTmax Pro 3.1.1
software was used to read the BCA assay absorbance results.
Antigen Presentation
Delivery of the TAT-mHER2/mHER2 was achieved by introducing the
antigen to APCs cultured in vitro from murine (Mus musculus) spleen. Five
different antigen concentrations were used, 2.5 µM, 1.25 µM, 0.625 µM,
0.3125 µM, and 0.15625 µM, as well as a PBS control. Female H2-Kb positive
C57BL/6 mouse spleens were used for the procedure. Spleen procurement began
with cervical dislocation of the mouse followed by wetting of the mouse with
70% ethanol. To remove the spleen the skin was first lifted and cut with scissors
to expose the abdominal muscle which was cut away as well to expose the spleen
(appears dark-red in color and is long and thin in shape). The spleen was excised
from the mouse and had all the connective tissue removed. Next, the spleen was
placed into a Petri plate with Roswell Park Memorial Institute media with 10 ml
of 10% fetal bovine serum (RPMI + 10% FBS). Using the frosted ends of two
glass microscope slides, cleaned with 70% ethanol and rinsed with PBS, the
mouse spleen was ground into a thin pulp into the RPMI + 10% FBS. The ground
spleen and the RPMI + 10% FBS were then aspirated into a 15 ml centrifuge tube.
An additional 5 ml of RPMI + 10% FBS was added to the Petri dish and rinsed on
the slides to collect any remaining splenocytes; this was also added to the 15 ml
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centrifuge tube. The splenocytes were centrifuged at 1250 rpm for 5 minutes to
pellet the cells. The RPMI + 10% FBS was aspirated and 1 ml Sigma red blood
cell (RBC) lysing buffer was added to lyse any RBCs. After one minute, 14 ml of
RPMI + 10% FBS was added and the splenocytes were centrifuged again at 1250
rpm for 5 minutes to pellet the cells. Following centrifugation, the RPMI + 10%
FBS was aspirated and 7 ml of fresh RPMI + 10% FBS was added to resuspend
the splenocytes. The 7 ml RPMI + 10% FBS/splenocyte suspension was
transferred to a 70 ml, 25 cm2 cell culture flask and incubated for two to four
hours at 37° C, 5% CO2. After incubating, all RPMI + 10% FBS media and nonadherent cells were removed by aspiration. The flask was scraped to harvest the
adherent cells (antigen presenting cells) and 12 ml of fresh RPMI + 10% FBS was
added to resuspend the dendritic cells for aliquoting. A 24-well plate was
prepared with 12 round coverslips (sterilized with 70% ethanol and rinsed with
PBS) placed inside 12 wells where 1 ml of the RPMI + 10% FBS/dendritic cell
suspension was aliquoted into each well and allowed to incubate for two hours at
37° C, 5% CO2.
Immunolocalization of HER2 Presentation in MHC Class I
To determine the MHC class I expression levels of the TAT-mHER2
antigen, a modified version of a direct enzyme-linked immunoabsorbent assay to
determine immunolocalization was employed and an Olympus BX51 Fluorescent
Microscope was used to visualize the fluorescence of the labeled antigen. The
antigen presenting cells obtained from the spleens of female H2-Kb positive
C57BL/6 mice were grown on untreated glass cover slips placed inside 24-well
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plates. After incubating for two hours in RPMI + 10% FBS media, the nonadherent cells were aspirated and 1 ml new media was added along with TATmHER2 acting as the antigen for the splenocyte APCs to uptake. Additionally,
mHER2 (not cross-linked with TAT) were also tested serving as a comparative
antigen in separate wells. Both antigens were added to each successive well in 25
µl volumes of decreasing concentrations (diluted in PBS) with each successive
dilution being half the concentration of the previous dilution, i.e. 2.5 µM, 1.25
µM, 0.625 µM, 0.3125 µM, and 0.15625 µM, as well as a PBS control. After the
addition of the antigen, the cells were incubated overnight to allow for antigen
processing. Next, the media was aspirated and the cells fixed with 1 ml of 4%
paraformaldehyde for 10 minutes, aspirated, and rinsed twice with PBS. The 4%
paraformaldehyde solution was prepared immediately prior to use by adding 0.6
grams of paraformaldehyde, 12 ml of dH2O, and 5 ml of 1 M NaOH to a beaker
which was heated to 70°C and stirred until the paraformaldehyde solubilized
(Doyle, 1996). The solution was cooled to 25°C, the volume was adjusted to 13.5
ml with dH2O, and 1.5 ml of 10 X PBS was added to bring the final volume to 15
ml (Doyle, 1996). The pH was adjusted to 7.4 using drops of 10% HCl and the
solution was sterile vacuum filtered through a 0.22 µm cellulose acetate filter
(Doyle, 1996). Twenty five microliters of goat serum were then added as a
blocking agent, allowed to incubate for five minutes at 37° C, 5% CO2, aspirated,
and washed twice with BD Pharmingen Stain Buffer with 2% FBS (Dulbecco’s
Phosphate-Buffered Saline with 2% fetal bovine serum, 0.09% sodium azide, pH
7.4); this blocking step was repeated three times. After blocking, 25 µl of the
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primary antibody 25-D1.16, diluted to 1:100 in BD Pharmingen Stain Buffer with
2% FBS, was added to each well and incubated for 60 minutes at 37° C, 5% CO2
and then washed three times over five minutes with PharMingen Stain Buffer.
This murine monoclonal antibody was produced by a hybridoma cell line
provided by Angel Porgador and Jonathan Yewdell and it recognizes MHC class I
molecules complexed with the amino acid sequence SIINFEKL (OVA257-264)
which TAT-mHER2 and mHER2 possess (Figure 4). The 25-D1.16 hybridoma
cell line was originally cultured in Dulbecco’s Modified Eagle Medium with 10%
heat inactivated fetal calf serum and then Iscove’s Modified Dulbecco’s Medium
with 10% FBS for antibody production. This hybridoma cell line produced
copious amounts of 25-D1.16 antibody.
A secondary antibody, AbCam biotin-conjugated rat anti-mouse
immunoglobulin, λ2 and λ3 light chain mAb (2B6ab) was then added to bind with
the 25-D1.16 primary antibody (also diluted in Pharmingen Stain Buffer, but at
double the concentration, 1:50) and allowed to incubate for an additional 60
minutes at 37° C, 5% CO2. After washing three times over five minutes using
PharMingen Stain Buffer, 25 µl of PharMingen Streptavidin-Fluorescein
Isothiocyanate Conjugate (Sav-FITC or simply FITC) was added in a
concentration that was double the concentration of the secondary antibody, 1:25,
to conjugate to the biotin complexed with the secondary antibodies for
immunofluorescence. This step and all subsequent steps were performed in lowlight conditions to preserve fluorescence. The cover slips within the wells were
then mounted on slides and counter stained with Vector Vectashield Mounting
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Medium for fluorescence with 4’,6-diamidino-2-phenylindole (DAPI) prior to
analysis with the fluorescent microscope. Splenocytes expressing TAT-mHER2
or mHER2 displayed green fluorescent points on the cell surface (Figure 5) under
the FITC filter and non-expressing cells were invisible or faintly colored. Three
images were taken of each cell (using Applied Imaging fluorescent imaging
software) under both the DAPI and FITC filters as well as an overlay of both
pictures combined (Figures 5, 6, and 7). It is interesting to note that the
concentration of TAT-mHER2 in these figures is at 0.15625 µM. Diluting each
antigen was done to determine when each reached a point of no longer being
recognized by the primary antibody 25-D1.16. TAT-mHER2 and mHER2 were
diluted as such: 2.5 µM, 1.25 µM, 0.625 µM, 0.3125 µM, 0.15625 µM, and a
PBS control.
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RESULTS
To compare the expression level of both antigens (mHER2 and TATmHER2), cells counts were taken of the number of positive cells, cells showing
FITC signaling, and the number of positive signals in each cell. The number of
positive signals per cell was determined by counting individual FITC signals on a
positive cell; for example, Figure 6 depicts nine positive FITC signals on that
particular cell. The number of positive signals in each cell was divided by the
number of positive cells resulting in the average number of positives per cell.
These counts were taken at each concentration, including the mHER2 and TATmHER2 PBS controls. Only cells displaying the processed antigen in MHC class
I were detectable in this assay due to the specificity of the 25-D1.16 mAb. The
eight amino acid SIINFEKL sequence inserted between the intracellular and
extracellular HER2 components must undergo antigen processing by the APCs in
order to be recognized by the 25-D1.16 mAb. Any antigen that did not undergo
cellular uptake and processing but was adhering APC’s outer-membrane would
not elicit any antigen/mAb interaction.
At every concentration level, except 0.15625 µM, there were more
positive TAT-mHER2 cells than mHER2 cells. Comparison of paired groups
showed a significant difference for TAT-mHER2-treated cells at 1.25 µM (Figure
8). The number of positive signals from the TAT-mHER2-treated cells was also
higher than the mHER2-treated cells at every concentration level however the
differences were not significant except at 1.25 µM and 0.625 µM (Figures 8 and
9). An asterisk denotes the statistically significant 1.25 µM and 0.625 µM TAT-
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mHER2 concentrations in Figures 8 and 9. The PBS controls (which were not
treated with either TAT-mHER2 or mHER2) also showed some low level positive
signals, but these were attributed to nonspecific background staining (Figures 8
and 9). Interestingly, the average number of positives per cell was higher for
mHER2 at all concentrations except at 0.625 µM and 0.3125 µM indicating that
while less cells displayed mHER2, those that did displayed it at higher levels
(Figure 10). These two concentration levels could show a possible optimal
concentration level for TAT-mHER2 cell delivery.
A t-test for the two correlated samples (mHER2 versus TAT-mHER2) at
each concentration was performed on both the number of positive cells and
positives per cell to determine if the sum of the change between the two groups
differed significantly from zero. The t-tests for these data revealed p-values that
were insignificant at every concentration except at 1.25 µM (positive cells) and
0.625 µM (positives per cell):
Concentration
2.5 µM
1.25 µM
0.625 µM
0.3125 µM
0.15625 µM
PBS Controls

p-value (Positive Cells)
0.16647
0.00097
0.10891
0.72527
0.31934
0.34791

Concentration
2.5 µM
1.25 µM
0.625 µM
0.3125 µM
0.15625 µM
PBS Controls

p-value (Positives per Cell)
0.56511
0.07529
0.00717
0.72930
0.55242
0.33247
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Additionally, three other concentration levels showed p-values that approached a
p-value of 0.05: 2.5 µM and 0.625 µM for positive cells and 1.25 µM for
positives per cell. Both the 1.25 µM and 0.625 µM concentrations showed a
correlation between the positive cells and positives per cell counts.
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DISCUSSION
Eliciting a cytotoxic immune response to cancer antigens, which are
essentially self-antigens, has traditionally been a major obstacle, due to the APCs
presenting these antigens in an MHC class II. The subsequent activation of CD4+
TH cells typically leads to the release of cytokines which in turn activate B
lymphocytes, macrophages, and CD8+ TC cells. However, the CD8+ TC cells
cannot induce apoptosis due to the lack of costimulatory signaling from the target
cell which leads to clonal anergy (Goldsby et al., 2000). This signal is triggered
by the interaction of CD80 on the APC with CD28 present on either CD4+ TH or
CD8+ TC cells.
Another factor involved with this ineffective immune response is downregulation of MHC class I expression on tumor cells which may allow the tumor
to escape CTL-mediated recognition (Goldsby et al., 2000). The immune
response may play a role in selecting tumor cells expressing lower levels of MHC
class I molecules by preferentially eliminating those cells expressing high levels
of MHC class I molecules and, with time, malignant tumor cells may express
progressively fewer MHC molecules and thus escape CTL-mediated destruction
(Goldsby et al., 2000). To compound this phenomenon, most tumors grow
rapidly and it quickly becomes futile for the immune system to target and kill
every tumor cell. Additionally, tumors can evolve to evade immune responses
either by failing to express a tumor antigen on its MHC molecule, having an
MHC mutation prevent MHC expression, or through production of
immunosuppressive cytokines (Abbas & Lichtman, 2001).
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Cross presentation is the immune system’s response to these tumor
evasion mechanisms. When an APC ingests a tumor cell, cross presentation
occasionally occurs leading to a CD8+ TC cell interaction, CD8+ TC cell
differentiation into a CTL, and finally apoptosis of tumor cells. The intracellular
mechanisms of cross-presentation are still unclear, but seem to involve
specialized subcellular compartments bearing characteristics of both the
endoplasmic reticulum and the endosome (Guermonprez et al., 2003). Taking
advantage of this ability possessed by APCs allows the immune system to keep
certain viruses and tumors in check even though these antigens would normally be
presented in an endogenous manner. Increasing cross presentation in APCs and
increasing the number of cross presenting APCs in general through the use of
PTDs has been attempted by a number of researchers. The attractive feature of
PTDs is the ability to enter a cell independent of any known receptor or endocytic
activity. Add to this that PTDs can be coupled to other, much larger molecules
and not lose their transducing properties presents a potential boon to
immunotherapy research.
Kim et al. (1997) and Shibagaki and Udey (2002) were able to
demonstrate the abilities of HIV-TAT PTD to induce the MHC class I pathway
and thus showing an alternative to traditional methods of DC pulsing. Recent
research by Tanaka, Dowdy, Linehan, Eberlein, and Goedegebuure (2003) and
Viehl et al. (2005) demonstrated successful protein transduction of cancer
antigens coupled with the HIV-TAT PTD and a subsequent induction of antigenspecific CTLs. All four studies demonstrated the efficiency by which proteins
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could be introduced into the MHC class I pathway over the traditional use of
tumor cell preparations such as tumor lysates and apoptotic tumor cells or DCtumor cell fusions (Tanaka et al., 2003). Other methods involving DNA, RNA, or
viral vectors containing tumor antigen genes were also not as efficient as PTD
transfer (Tanaka et al., 2003).
Vaccine production has continually been stymied because of MHC class II
elicitation in lieu of MHC class I. In all likelihood inducing just a MHC class I
response would be virtually impossible, however Viehl et al. (2005) demonstrated
that TAT coupled with mammaglobin (a breast cancer-associated protein)
transduced dendritic cells induces both CD4 and CD8 mammaglobin-specific T
cells. This scenario shows great promise that a vaccine could be developed using
this technology. Effective antitumor immune responses are thought to require the
contribution of both CD4+ and CD8+ T cells, making protein transduction of
tumor antigens a viable strategy because of HIV-TAT’s ability to cross the cell
membrane of most mammals (Schwarze et al., 2000; Viehl et al., 2005).
The objective for this study was to analyze and quantitate the cross
presentation of HER2 antigens coupled with the PTD HIV-TAT compared to
HER2 alone. Our approach entailed using HIV-TAT to transport exogenous
proteins to the cytosol where they would enter the endogenous pathway.
Immunolocalization analysis was conducted using the mAb 25-D1.16. This mAb
is specific for the peptide sequence SIINFEKL, the eight amino acid residues of
chicken ovalbumin (residues 257-264), found between the extracellular HER2 and
intracellular HER2 components of our TAT-mHER2 and mHER2 proteins and

35

labeling with mAb 25-D1.16 was used to display in an MHC class I molecule on
murine splenic APCs. Labeling indicated that there was an increase in MHC class
I expression using TAT-mHER2 compared to mHER2 and that increase was
significant using 1.25 µM and 0.625 µM antigen concentrations (Figures 8 and 9).
We expected to see greater MHC class I presentation following incubation with
TAT-mHER2; while greater presentation was seen, the increased presentation was
not as robust as expected.
While our hypothesis was not fully supported by the results of this study,
similar studies conducted previously by Tanaka et al. (2003) and Viehl et al.
(2005) showed more favorable results thus warranting further investigation.
Several factors may have contributed to our results not supporting our hypothesis:
the particular TAT-mHER2 sample used in this study may not have been fully
functional; if the TAT-mHER2 was functional, there may have been no
ubiquitination of the protein and therefore no antigen processing through the
endocytic pathway; preparing the splenocytes for in vitro analysis may have
placed too much stress on the murine splenic dendritic cells resulting in a
decreased ability to process antigens; the assay developed for this study may not
have been sensitive enough. Additionally, determining if the antigen was
delivered into the cell or if the antigen just merely coated the cell surface, with no
uptake, requires further study. Further, whether or not the antigen induced an
immune response and if the actual cellular uptake of the antigen was through
protein transduction need evaluation. Analyzing and quantitation of the cross
presentation of HER2 tumor antigens could be optimized through the use of
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fluorescence-activated cell sorting (FACS) or green fluorescent protein. Using
both of these methods would allow the assay of live cells. Improving antigen
delivery could potentially be improved through adding another PTD protein to the
antigen (i.e. TAT-TAT-mHER2 or TAT-mHER2-TAT). Accomplishing this
construct may require the use of cosmids, bacterial artificial chromosomes, or
yeast artificial chromosomes to accommodate the larger genetic sequence.
Additionally, determining if there is any specificity to PTD/cargo protein
combinations might allow future study into optimizing antigen uptake.
Expanding this study to an in vivo model may also improve more efficient TATmHER2 delivery and antigen presentation.
Continuing and expanding research into PTD biotechnology, particularly
in regards to immunotherapy and the mechanistic means by which PTDs gain cell
entry, could produce great gains in our ability to present cancer associated
antigens to the immune system and may eventually lead to improved cancer
patient outcomes.
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APPENDIX A

FIGURES

Figure 1: (a) PTD and protein ‘X’ complex, (b) protein ‘X’ being transported
through the lipid bilayer by the PTD, and (c) refolding by HSP90 for reactivation
(Schwarze et al., 2000).
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Figure 2: Plasmid pTriExSN-TAT-mHER2 containing PTD-TAT, extracellular
and intracellular HER, and SIINFEKL. The gene encoding TAT was inserted
first with a linker followed by extracellular HER2 (HER2EC1/2), SIINFEKL, and
intracellular HER2 (HER2IC1/4).
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58.8 kDa

Figure 3: SDS-PAGE confirming presence of TAT-mHER2. The left lane
contains 10 µl of sample; the right lane contains 15 µl.
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50 kDa
Heavy Chains
25 kDa
Light Chains

Figure 4: SDS-PAGE confirming the presence of the monoclonal antibody 25D1.16. Left lane contains 5 µl of sample; the right lane contains 10 µl. The
darker, thicker band is the immunoglobulin heavy chain; the two smaller bands
are the two light chains (below the heavy chain).

46

Figure 5: DAPI-stained APC with 0.15625 µM of TAT-mHER2 antigen (DAPI
filter, magnification ×1000).
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Figure 6: TAT-mHER2 (0.15625 µM) expressed on APC cell surface bound to
25-D1.16 mAb which is bound to biotin-conjugated rat anti-mouse
immunoglobulin and stained with SAv-FITC; binding sites are intensely bright
points (FITC filter; magnification ×1000). Note: the FITC-stained object in the
upper-right corner is background interference.
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Figure 7: DAPI-stained APC and FITC-stained TAT-mHER2 (0.15625 µM)
overlay (DAPI and FITC filters overlaid; magnification ×1000). Note: the FITCstained object in the upper-right corner is background interference.
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Figure 8: Number of cells positive for mHER2 and TAT-mHER2 from antigen concentrations of 2.5 µM to 0 µM.
The asterisk denotes a statistically significant p-value.
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Figure 9: Number of positive signals per cell for mHER2 and TAT-mHER2 from antigen concentrations of 2.5 µM to 0 µM.
The asterisk denotes a statistically significant p-value.

Positives per Cell

52

0

0.5

1

1.5

2

2.5

3

3.5

2.5 µM
mHER2

2.483

2.5 µM
TATmHER2

2.179

1.25 µM
mHER2

1.957

1.25 µM
TATmHER2

1.698

0.625 µM
mHER2

1.409

0.3125 µM 0.3125 µM
mHER2
TATmHER2

1.625 1.667

Concentration (µM)

0.625 µM
TATmHER2

2.364

0.15625
µM
mHER2

3.091

0.15625
µM TATmHER2

1.438

PBS
PBS (TAT(mHER2) mHER2)
Control
Control

1.286 1.364

Figure 10: Average number of positive signals per cell for mHER2 and TAT-mHER2 from antigen concentrations of 2.5 µM to
0 µM.
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